SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $272,946 | +53.4% | 18,798 | +121.2% | 0.00% | – |
| Q2 2023 | $177,905 | -82.3% | 8,500 | -78.5% | 0.00% | -100.0% |
| Q4 2022 | $1,007,691 | +3775.7% | 39,595 | +2513.5% | 0.00% | – |
| Q2 2021 | $26,000 | -98.2% | 1,515 | -97.6% | 0.00% | -100.0% |
| Q1 2021 | $1,432,000 | -39.7% | 64,102 | -40.0% | 0.00% | -40.0% |
| Q4 2020 | $2,375,000 | +28.9% | 106,789 | -14.6% | 0.01% | +25.0% |
| Q3 2020 | $1,843,000 | +19.6% | 125,036 | +20.1% | 0.00% | +33.3% |
| Q2 2020 | $1,541,000 | +4.7% | 104,122 | -22.6% | 0.00% | -25.0% |
| Q1 2020 | $1,472,000 | +16255.6% | 134,449 | +6622.4% | 0.00% | – |
| Q4 2018 | $9,000 | -71.9% | 2,000 | -48.7% | 0.00% | – |
| Q3 2018 | $32,000 | +14.3% | 3,900 | -2.5% | 0.00% | – |
| Q2 2018 | $28,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |